The changing phenotype of Inflammatory Bowel Disease by Moran, Carthage et al.
Title The changing phenotype of Inflammatory Bowel Disease
Author(s) Moran, Carthage; Sheehan, Donal; Shanahan, Fergus
Publication date 2016-11
Original citation Moran, C., Sheehan, D. and Shanahan, F. (2016) 'The changing
phenotype of Inflammatory Bowel Disease', Gastroenterology Research
and Practice, 1619053 (9pp). doi: 10.1155/2016/1619053
Type of publication Article (non peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1155/2016/1619053
Access to the full text of the published version may require a
subscription.
Rights © 2016, the Authors. This is an open access article distributed under
the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/3683
Downloaded on 2017-09-04T23:30:23Z
Review Article
The Changing Phenotype of Inflammatory Bowel Disease
Carthage Moran, Donal Sheehan, and Fergus Shanahan
Department of Medicine and the APC Microbiome Institute, University College Cork,
National University of Ireland, Cork, Ireland
Correspondence should be addressed to Carthage Moran; cmoran@ucc.ie
Received 8 September 2016; Revised 1 November 2016; Accepted 8 November 2016
Academic Editor: Bjørn Moum
Copyright © 2016 Carthage Moran et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
It is widely known that there have been improvements in patient care and an increased incidence of Inflammatory Bowel Disease
(IBD) worldwide in recent decades. However, less well known are the phenotypic changes that have occurred; these are discussed
in this review. Namely, we discuss the emergence of obesity in patients with IBD, elderly onset disease, mortality rates, colorectal
cancer risk, the burden of medications and comorbidities, and the improvement in surgical treatment with a decrease in surgical
rates in recent decades.
1. Introduction
The incidence of Inflammatory Bowel Diseases (IBD) is
increasing worldwide [1]. There continues to be remarkable
changes in the incidence of IBD amongst different ethnic
groups in recent decades as they are exposed to increasingly
industrialized environments [2]. Less well known are the
phenotypic changes that have occurred in patients with IBD
(see Table 1) [3].
2. Disease Phenotype
Disease phenotype at diagnosis of IBD has changed in recent
decades [3]. A Danish study, investigating consecutive popu-
lation based cohorts, describes these changes: the proportion
of Crohn’s disease (CD) amongst total IBD cohort increased
and the prevalence of CD and ulcerative colitis (UC) patients
who were smokers at diagnosis decreased with time. The
median age at diagnosis was stable over five decades for CD
patients but increased from 34 years to 38 years in patients
with UC [4].
A Dutch population study of patients newly diagnosed
in 2006 found that 61% of patients with CD had ileal
involvement, 31% had stricturing or penetrating disease [5].
Mean age at diagnosis for CD patients was 36.7 years. In the
Olmsted County cohort study (1970–2004), 64% of patients
at diagnosis had ileal involvement and 18.6% complicated
disease [6]. The phenotype at diagnosis in patients with
UC is generally split equally between proctitis, left sided
disease, and pancolitis [7, 8]. The proportion of patients
presenting with pancolitis increased over the last five decades
in Denmark [4].
The phenotype of disease amongst Asian patients with
IBD has been described to differ from that of patients
from North America and Western Europe [9]. Male pre-
dominance [10] increased ileocolonic disease has been
described amongst Asian cohorts of patients with CD.
However a prospective study failed to show significant
difference in disease location between Australian and Asian
cohorts [8] (see Table 2 for disease location at diagno-
sis amongst different geographical cohorts). A follow-up
study of this cohort revealed that disease behavior for
Asian patients with CD can be as severe as in the West
[11].
IBD in patients with Primary Sclerosing Cholangitis
(IBD-PSC) represents a distinct phenotype. There is a male
predominance, with three-quarters of patients having coex-
isting UC and PSC [12]. In patients with UC there is an
increased risk of pancolitis [12] and subsequent pouchitis (not
related to the severity of liver disease) [13] and colorectal
cancer [14], in addition to risks of cholangiocarcinoma, liver
failure, and gallbladder cancer. In patients with coexistingCD
and PSC, colonic disease is present in the vast majority of
patients [12]. Prolonged duration of IBD is associated with an
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Table 1: The changing phenotype of patients with IBD [3].
Feature Comment Reference
Increased BMI
(i) Prevalence of obese and overweight patients in a Scottish IBD population was 18% and 38%,
respectively. [19]
(ii) 17% of patients with CD in an Irish cohort were obese compared to 12% of controls. [16]
(iii) A third of patients with IBD attending metropolitan health services in Texas were obese. [20]
(iv) Increased weight of patients with CD enrolling in clinical trials (1991–2008). [21]
(v) 23% of paediatric patients with IBD in United States found to be overweight or obese. [30]
Decreased rate of surgery
(i) Cumulative probability of first major surgery at 9 years decreased from 50% (1979–86) to 23%
(2003–11) in patients with CD and 14% to 9% in patients with UC. [69]
(ii) Decreased risk of surgery in patients diagnosed with CD after 1996, associated with increased
specialist care. [70]
(iii) Reduced surgical rates in patients with CD associated with increased and earlier
immunomodulator use. [71, 72]
Reduced proportion of
patients with short bowel
syndrome
(i) Largely due to improvements and specialization of surgical care.
(ii) Partially due to improvements in medical treatments.
Almost a
universal
observation
Increasing prevalence of
elderly onset IBD
(i) Increased proportion of colonic disease and inflammatory behavior, in elderly patients with
CD. [38, 46]
(ii) Progression of disease behavior less than in younger patients. Milder disease course than
younger cohorts. [38]
Reduced risk of colorectal
cancer (CRC) in recent
decades
(i) Meta-analysis of population studies found that CRC elevated in patients with IBD, but not as
high as previously reported. [73]
(ii) Nationwide study in Denmark found that risk of CRC in patients with UC no longer exceeds
that of general population. [74]
Table 2: Disease location at diagnosis as per Montreal Classification.
Hungary [75] Sweden [76, 77] Netherlands [5] Australia [8] Asia∗ [8]
Crohn’s disease
Ileal 20.2% 28% 21.4% 31% 31%
Colonic 35.6% 49% 36.3% 24% 24%
Ileocolonic 44.2% 23% 38.8% 45% 45%
Ulcerative colitis
Proctitis 26.8% 32% 29% 32% 37%
Left sided colitis 50.9% 31% 52.8% 27% 32%
Pancolitis 22.3% 31% 18.4% 41% 21%
∗Mainland China, Hong Kong, Indonesia, Macau, Singapore, Sri Lanka, andThailand.
increased risk of cholangiocarcinoma in patients with IBD-
PSC [15].
3. Obesity
Malnutrition has long been recognized as a complication of
IBD. Previously attention was focused on patients who were
underweight, but obesity is increasingly associated with IBD
[16]. Obesity has reached epidemic proportions in western
countries, becoming an equal if not greater contributor to
burden of disease than smoking in the United States [17].
Regression in life expectancy in the 21st century is predicted
if the rate of obesity goes unabated [18].
A Scottish study reported that the prevalence of obese
and overweight patients in an IBD population was 18% and
38%, respectively [19]. In the overweight/obese cohort of UC
patients there were higher levels of surgery, but the converse
was true for the CD cohort. Interestingly in this study there
were significantly more obese patients with CD than UC [19].
A third of patients with IBD in a cohort from Texas were
obese [20]. Patients with CD enrolling in clinical trials had
an increase in weight and disease activity in the last 20 years
[21].
Mesenteric fat has long been shown to be an indicator
of regional disease activity in CD. “Creeping fat” [22], or fat
wrapping, has been used by surgeons to help identify the
most diseased regions of bowel. However the role of obesity
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in development of IBD is unclear. Adipose tissue is not inert;
it is well known to be actively involved in both systemic
and intestinal inflammatory responses in patients with IBD
[23]. A large prospective study found no association between
obesity and development of incident IBD [24]. This study
had a predominance of middle-aged subjects. IBD tends to
present at an earlier age. Conversely, a recent case control
study investigated a cohort of patients aged 50 to 70 years,
finding obesity was more common in patients with CD than
community controls [25]. A subsequent study found that
obese women were at elevated risk of developing CD [26].
Early paediatric IBD cohorts have been described as
being underweight and malnourished, with lower BMI than
background population distribution [27]. However, more
recent studies reveal that children with IBD are affected by
current population trends towards weight gain; 20–30% and
10%ofUCandCD incident caseswere overweight or at risk of
being overweight as per BMI [28]. These studies also showed
that 7–9% and 22–24% of UC and CD incident cases had a
low BMI [28].
A large, multicenter cohort study of children with IBD
performed in the US, where childhood obesity is epidemic
[29], found the overall prevalence of overweight or obesity
in this IBD population to be 23%, with 30% and 20% of
UC and CD populations overweight or obese [30]. Paediatric
patients with CD who are overweight or obese have higher
rates of IBD-related surgery, similar to findings in adult
populations [31]. Higher use of corticosteroids was found in
the overweight/obese UC (35% vs 27%) but not CD group.
The rise of obesity is especially concerning in patients
with IBD as it is a known risk factor for colorectal cancer
(CRC) [32] and can affect efficacy of medical treatment,
including anti-TNF therapies [33, 34]. Obesity is associated
with increased blood loss, operative time, and conversion to
open surgery in patients with IBD undergoing laparoscopic
surgery [35].
4. Elderly Onset IBD
The proportion of the world’s population that is elderly
is increasing [36]. The prevalence of IBD is increasing
worldwide [2], thus managing elderly patients with IBD is an
increasing clinical encounter. There is a paucity of literature
regarding elderly onset IBD in comparison to “early” onset
IBD. This is compounded by the fact that in many clinical
trials elderly patients are excluded from study enrollment.
Roughly 10% of patients present with first presentation
of IBD aged greater than 65 years [37]. A recent population
based cohort study in northern France described the natural
history of elderly onset (>60 years) IBD. 5% and 12.5% of
incident cases of CD and UC, respectively, were classified as
elderly onset over study timeframe (1988–2006). The clinical
history at diagnosis and course of disease was milder in
elderly onset IBD than younger onset disease [38]. Half of
the patients in this large cohort did not undergo surgery nor
were exposed to medications other than 5-ASA [38]. Patients
with elderly onset IBD had lower IBD-specific healthcare
utilization than patients with earlier onset IBD [37]. In
contrast, a survey of hospital discharges suggested geriatric
IBD patients accounted for a quarter of all IBD-related
hospitalizations [39], with higher mortality than younger
patients. This study included all patients with IBD older than
65, not just patients with elderly onset IBD [39]. Elderly onset
IBD is not associated with an increased risk of intestinal
cancer; however there is an increased risk of developing lym-
phoproliferative (not associated with thiopurine exposure)
and myeloproliferative disorders [40].
Elderly patients with acute severe UC (ASUC) had worse
outcomes compared to younger patients in audits of IBD care
in the United Kingdom. Patients aged greater than sixty years
with ASUC had a roughly 4% mortality, compared to 0.1%
if younger than sixty [41]. Patients aged greater than eighty
with ASUC had mortality rates of 10% [41]. A retrospective
Japanese study reported poor outcomes in elderly patients
with UC undergoing emergency surgery, with a mortality
rate of 27% at 30 days postoperatively for emergency surgery
compared to 1% for elective surgery [42].
Colonic CD is more common than small bowel disease
or ileocolonic disease in elderly onset disease [43, 44]. There
is also a greater tendency for inflammatory, uncomplicated
behavior [43] with a relatively low proportion of patients
progressing to complicated disease (9%) [38, 45]. Elderly
onset UC is characterized by left sided or extensive colitis at
presentation, with disease extension rare [38].
In geriatric patients with IBD, longer disease duration is
associated with Vitamin D, Vitamin B12, and iron deficiency
[46]. Older patients have been shown to have an expedited
time to referral, investigation, and diagnosis than younger
patients [47]. Other diseases that can mimic symptoms
of IBD include diverticulosis, NSAID colitis, microscopic
colitis, and ischaemic colitis. Extensive biopsy sampling
and vigilance are necessary in order to avoid an erroneous
diagnosis purely based on histological mimicry of changes
seen in segmental colitis associated with diverticular disease
(SCAD), when diagnosing IBD in the presence of diverticu-
losis coli [48].
5. Comorbidities
As the phenotype of IBD changes, so do comorbidities.
Studies suggest that fatty liver disease is more common than
PSC in patients with IBD [49]. The prevalence of PSC in IBD
cohorts is estimated to be less than 5% [49, 50], although
a recent study revealed that 8% of patients with long-term
IBD screened with magnetic cholangiography had probable
PSC (these patients had subclinical PSC, that is, no symptoms
and normal liver function tests) [51]. Nonalcoholic fatty liver
disease in patients with IBD is common, with estimated
prevalence of 8 to 23% [49, 52]. Patients with IBD develop
nonalcoholic fatty liver disease (NAFLD) with less metabolic
risk factors compared to patients without IBD [52]. The rate
of NAFLD likely depends on environmental and genetic risk
factors of study population, as a recent prospective Swedish
study detected lower rates of NAFLD than American studies
[53]. Disease specific risk factors for NAFLD in patients
with IBD include small bowel surgery, use of steroids, and
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disease duration and activity [52, 54]. As the prevalence
of NAFLD and subsequently nonalcoholic steatohepatitis
induced cirrhosis, increases in patients with IBD, liver failure,
and transplantation will complicate management of patients
with IBD. Concomitant chronic liver disease doubles the
inpatient mortality rate in patients with IBD [55].
It is well known that patients with IBD are at increased
risk of developing venous thromboembolism (VTE) [56, 57].
Patients with IBD are at increased risk of developing VTE
upon hospital discharge compared with other patients [58].
The inflammatory cascade that increases risk of VTE likely
also places patients with IBD at increased risk of heart failure
[59] and atrial fibrillation [60] during periods of disease
activity. Flares of disease are also associated with increased
risk of myocardial infarction, stroke [61], and cardiovascular
death [62]. A recent meta-analysis concluded that patients
with IBD are at increased risk of ischaemic heart disease,
but not of cardiovascular mortality [57]. Further studies are
needed to investigate the role of medications and lifestyle
factors in patients with IBD to clarify the role their role in
the development of cardiovascular disease.
Anxiety and depressive symptoms commonly affect
patients with IBD [63] and are associated with body
image dissatisfaction [64] and nonadherence to medica-
tion [65]. Evidence suggests that treating mood disorders
can improve IBD disease activity [66, 67]. Concomitant
treatment of mood disorders with antidepressants (multiple
classes including tricyclic antidepressants and selective and
nonselective serotonin reuptake inhibitors) reduced IBD
relapse and steroid use in a retrospective case control study
[67]. Tricyclic antidepressants can also improve ongoing GI
symptoms in patients with adequate IBD therapy, as defined
by their physician [68]. Symptom response was similar in a
cohort of patients with IBD compared to group of patients
with IBS [68].
6. Medication Burden
Patients with IBD are often prescribed multiple medica-
tions. Patients with IBD have greater use of antidepressants,
sedatives, and analgesics (including narcotic analgesics)
than matched controls [78]. Older patients with IBD are
at increased risk of polypharmacy and potential adverse
medication interactions [79]. An American study found that
half of patients with CD met criteria for polypharmacy [80]
and that this finding correlated with decreased quality of life
and increased disease activity.
Narcotic use was identified in 13% of this cohort, and
narcotic use was associated with increased use of other
medications, including neuropsychiatric medications [81].
A Canadian population study showed that 5% of patients
with IBD will become heavy opiate users within 10 years of
IBD diagnosis [82]. An American study found that 70% of
patients hospitalized with IBD as primary indication were
given narcotics [83]. Factors associated with narcotic use
include history of surgery, smoking, and outpatient narcotic
use [83]. Healthcare models affect rates of narcotic use
amongst patients with IBD, as demonstrated by the variance
of narcotic use in different countries and an Australian study,
which demonstrated that the introduction of nurse specialists
reduced narcotic use amongst patients with IBD [84]. Our
anecdotal evidence would be that narcotic use has decreased
in recent decades. This is likely secondary to improved
medical care and recognition of psychological issues.
7. Mortality
There is an increased mortality rate in patients with CD
[85, 86] compared to the general population, with conflicting
evidence as to relative mortality rates in patients with UC
[86, 87]. A population based Canadian study found that
there was an increased mortality rate in both CD and UC
in the first year after diagnosis compared to the general
population, but this only persisted beyond a year in CD
and in those who underwent gastrointestinal surgery [88].
A meta-analysis of population based and inception cohorts
demonstrated an elevated overall mortality for patients with
both UC and CD, with standardized mortality ratios of 1.19
(95% confidence interval, 1.06–1.35) and 1.38 (95% confidence
interval, 1.23–1.55) [86]. This meta-analysis revealed that
summary mortality rate for CD remained constant over time
but improved for UC [86].
A large Danish population study found that mortality in
patients with UC decreased over three decades, secondary
to decreased mortality from colorectal cancer, suicide, and
gastrointestinal disorders [89]. Unfortunately patients with
CD were still found to have 50% greater mortality compared
to general population, and this did not change over study
period of 1982 to 2010 [89]. A diagnosis of PSC was identified
as a predictor of premature mortality in an Irish cohort of
patients with IBD [90].
8. Reduced Risk of Colorectal Cancer?
The risk of CRC in patients with IBD is less than previ-
ously reported (meta-analysis of population based studies
described a pooled standardized incidence ratio of 1.7 [73])
and is not increased in all patients [91]. The incidence of
colorectal cancer (CRC) in patients with UC has decreased
in the last few decades [92]. A nationwide Danish cohort
found that patients diagnosed with UC in the 1980s were at
increased risk of CRC compared to background population;
however that excessive risk of CRC has declined and no
longer exceeds that of the general population [74]. Extensive
colonic disease, concomitant PSC, young age at diagnosis,
and longer duration of disease are at increased risk of
developing CRC in patients with IBD [73, 74].
Why the risk of CRC is declining in patients is not
fully understood. There is conflicting evidence on the role
of 5-ASAmedications, thiopurines, and biologic medications
as chemopreventive agents [93]. Endoscopic surveillance of
patients with IBD is recommended, and colonoscopy in
preceding three years is associated with reduced incidence
of CRC [94]. These finding are in keeping with a German
study that found colonoscopy within preceding 10 years was
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associated with a 77% reduced risk of CRC in the general
population [95].
The decrease in gastrointestinal malignancies observed
in recent decades has been accompanied by an increase in
nongastrointestinal malignancies [96]. There is an increased
risk of developing haematological malignancies [91]. Ongo-
ing thiopurine exposure of greater than one year is associated
with increased risk of lymphoma in patients with IBD.
This elevated risk is not persistent after thiopurines are
discontinued [97].
Patients with IBD on immunosuppressive therapy appear
to be at increased risk of high grade cervical dysplasia or
cancer [98] and melanomatous and nonmelanomatous skin
cancer [99, 100].
9. Reduced Surgical Rates
The risk of IBD-related surgery has decreased in recent
decades [101]; see Table 1 [3]. Advances inmedications [71, 72]
and specialization of management of patients with IBD [70],
in addition to improved surgical techniques, have led to
reduced rates of surgery. Further studies on the impact of
biological agents on surgical rates are needed.
Surgical intervention remains integral to managing
patients with complex IBD and can improve patients’ quality
of life [102] and should not always be seen as a poor outcome,
especially in those with localized disease [103].
10. Conclusion
Further studies are needed to investigate the relationship
between ongoing chronic inflammation and systemic med-
ications and the development of obesity and cardiovascular
disease. Gastroenterologists need to be aware of emerging
comorbidities in patients with IBD. Caution is needed in
extrapolating results from existing randomized control trials,
as most patients would be ineligible to participate in recent
trials, whether due to their comorbidities, medication use, or
disease phenotype [104].
The increased prevalence of obesity poses a challenge in
the management of patients with IBD, not least due to the
potential of further increased risk of CRC. Positive lifestyle
habits such as exercise and smoking cessation, which may
have diseasemodifying behavior [105], should be encouraged
regularly. As the proportion of elderly patients with IBD
increases, the potential for polypharmacy and adverse medi-
cation interactions also increases. Thus close liaison between
gastroenterologists and patient’s general physicians needs to
remain an integral in the care of patients with IBD.
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